John S Petersen

This inventor holds 40 USPTO granted patents and 10 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Innovations. Top assignees: Syndevrx, Inc., Geltex Pharmaceuticals, Inc., Genzyme Corporation. Active years: 1993-2022.

USPTO Granted Patents = 40 (Patent Applications = 10)

% Patents Active = 80.0

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.0

ph-index = 13

Forward Citations = 637(Granted Patents)

Company Filing History:

Geltex Pharmaceuticals, Inc.

Millipore Corporation

patents

5. 1 out of 3

Nitric Biotherapeutics, Inc.

patents

6. 1 out of 137

Waters Investments Limited

patents

Years Active: 1993-2022

Loading Chart...

Areas of Expertise:

MetAP2 Inhibitors

Polymer-Conjugated Drugs

Cholesterol Treatment

Fumagillol Derivatives

Direct Compression

Bile Acid Sequestrants

Hydrophobic Sequestrants

Polyvalent Polymers

Chiral Surfactants

Hypercholesterolemia

Capillary Separations

Obesity Treatment

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11304944 - MetAP2 inhibitors and methods of treating obesity (2022-04-19),

2. 10722532 - Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof (2020-07-28),

3. 10588904 - METAP2 inhibitors and methods of treating obesity (2020-03-17),

4. 10287277 - Fumagillol derivatives and polymorphs thereof (2019-05-14),

5. 10159692 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2018-12-25),

6. 10010544 - METAP2 inhibitors and methods of treating obesity (2018-07-03),

7. 9969722 - Fumagillol derivatives and polymorphs thereof (2018-05-15),

8. 9931358 - Direct compression polymer tablet core (2018-04-03),

9. 9895449 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2018-02-20),

10. 9757373 - MetAP2 inhibitors and methods of treating obesity (2017-09-12),

11. 9750737 - METAP2 inhibitors and methods of treating obesity (2017-09-05),

12. 9730955 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2017-08-15),

13. 9585909 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2017-03-07),

14. 9579343 - Direct compression polymer tablet core (2017-02-28),

15. 9433600 - METAP2 inhibitors and methods of treating obesity (2016-09-06),

Title: Innovations by John S. Petersen in MetAP2 Inhibitors

Introduction

John S. Petersen, based in Acton, MA, is a prolific inventor with an impressive portfolio of 40 patents. His research primarily focuses on the development of MetAP2 inhibitors, which have significant implications for treating obesity and metabolic disorders. His inventions seek to advance therapeutic methods in weight management and metabolic health.

Latest Patents

Among his latest innovations are patents concerning modified or polymer-conjugated MetAP2 inhibitors. These inventions relate to methods for preventing and treating obesity, improving insulin sensitivity, and enhancing glycemic control. The inventive approach combines pharmacological compounds with polymer conjugation to enhance efficacy and pharmacokinetic properties. His patents explore various therapeutic applications of these inhibitors, demonstrating a commitment to advancing medical treatments relevant to metabolic syndrome.

Career Highlights

Throughout his career, John has worked with notable companies such as Syndevrx, Inc. and Geltex Pharmaceuticals, Inc. His contributions have accelerated research and development efforts in the pharmaceutical sector, particularly in new therapeutic methodologies that are vital for patient care in obesity-related health issues.

Collaborations

John Petersen has collaborated with esteemed professionals in his field, including Stephen Randall Holmes-Farley and Pradeep K. Dhal. These partnerships have enriched his research endeavors and have contributed to the successful development of innovative therapeutic strategies.

Conclusion

John S. Petersen stands out as a leading inventor in the field of MetAP2 inhibitors, with a substantial number of patents that reflect his dedication to advancing scientific knowledge and healthcare solutions. His latest work continues to hold promise for improving the treatment landscape for obesity and related metabolic disorders.